WASHINGTON — Two outstanding Democratic lawmakers are requesting that the Federal Commerce Fee examine whether or not value hikes for 2 blockbuster blood thinners have been illegally coordinated by Janssen and Bristol Myers Squibb.
Sen. Amy Klobuchar (D-Minn.), the chair of the Senate Judiciary Committee’s subcommittee on antitrust enforcement, and Rep. Katie Porter (D-Calif.), a rising star within the Democratic Social gathering and a member of the Home’s oversight panel, wrote to the FTC on Monday concerning what they referred to as “parallel” value hikes on Xarelto and Eliquis, medication that sufferers take to forestall coronary heart assaults, strokes, and blood clots.
Unlock this text by subscribing to STAT+ and revel in your first 30 days free!
